Adinda Baten on Muck Rack

Adinda Baten

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Adinda

Contact Adinda, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER + HER2 − breast cancer: a randomized phase 2 trial

|
By Alex De Caluwe, Isabelle Desmoulins, Kim Cao, Vincent Remouchamps, Andrea Garcia, Andrea García, David Venet, Luca Arecco, Elisa Agostinetto, Guilherme Nader-Marta, Zoe Denis, Jennifer Dhont, Paulus Kristanto, Xavier Catteau, Denis Larsimont, Roberto Salgado, Philip Martin Poortmans, John Stagg, Christos Sotiriou, Martine Piccart, Michail Ignatiadis, Emanuela Romano, Laurence Buisseret, Adinda Baten, Eleonore Longton, Karine Peignaux
| Nature Verified
Abstract Patients with estrogen receptor-positive (ER+), HER2-negative, early breast cancer (BC) have low pathologic complete response (pCR) rates following neoadjuvant chemotherapy. Immune checkpoint inhibitors (ICIs) provide limited benefit in programmed death-ligand 1 (PD-L1)-negative tumors, characterized by an immune-cold tumor microenvironment.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified